You can buy or sell Zai Lab and other stocks, options, ETFs, and crypto commission-free!
Zai Lab Limited American Depositary Shares, also called Zai Lab, is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. Read More The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.
52 Week High
52 Week Low
Seeking AlphaMay 16
Zai Lab on go with China study of antibiotic combo
The China National Medical Products Administration has signed off on Zai Lab's (ZLAB -4% ) application to conduct a Phase 3 clinical trial there evaluating ETX2514SUL, a fixed-dose combination of a broad spectrum β-lactamase inhibitor with sulbactam, for the treatment of pneumonia and blood stream infections caused by carbapenem-resistant the bacterium A. baumannii.
Yahoo FinanceMay 9
Zai Lab Announces Participation at Upcoming May Conferences
SHANGHAI, China, May 09, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of the senior management team will participate in four upcoming conferences in May.
Yahoo FinanceMay 3
Here’s What Hedge Funds Think About Zai Lab Limited (ZLAB)
Is Zai Lab Limited (NASDAQ:ZLAB) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. It's not surprising given that hedge funds have access to better information and more resources to find the winners in the stock market. Zai Lab Limited (NA...
Expected Aug 29, Pre-Market